Mumps Pipeline Review, H2 2018 Featuring Cadila Healthcare Ltd, GlaxoSmithKline Plc & Sinovac Biotech Ltd - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--Sep 25, 2018--The ” Mumps - Pipeline Review, H2 2018 ” drug pipelines has been added to ResearchAndMarkets.com’s offering.
Mumps - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Mumps (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Mumps (Infectious Disease) pipeline guide also reviews key players involved in therapeutic development for Mumps and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/ Universities/ Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and IND/CTA Filed stages are 2, 1, 1 and 1 respectively. Similarly, the Universities portfolio in Phase II and Preclinical stages comprises 1 and 1 molecules, respectively.
Mumps (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Key Topics Covered:Introduction Report Coverage Mumps - Overview Mumps - Therapeutics Development Pipeline Overview Pipeline by Companies Pipeline by Universities/ Institutes Products under Development by Companies Products under Development by Universities/Institutes Mumps - Therapeutics Assessment Assessment by Route of Administration Assessment by Molecule Type Mumps - Companies Involved in Therapeutics Development Cadila Healthcare Ltd GlaxoSmithKline Plc Sinovac Biotech Ltd For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/8d9qqt/mumps_pipeline?w=4.
View source version on businesswire.com:https://www.businesswire.com/news/home/20180925006223/en/
Laura Wood, Senior Manager
For E.S.T. Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics:Infectious Diseases Drugs
INDUSTRY KEYWORD: EDUCATION UNIVERSITY HEALTH CLINICAL TRIALS INFECTIOUS DISEASES PHARMACEUTICAL RESEARCH SCIENCE
SOURCE: Research and Markets
Copyright Business Wire 2018.
PUB: 09/25/2018 05:44 PM/DISC: 09/25/2018 05:44 PM